A synaptic focus
A research approach centered on the biological pathways involved in neuronal connections, cognition, and function.
Neuracura Therapeutics · Alzheimer’s research
Investigating Bryostatin-1 to support the connections behind cognition and everyday life in moderately severe Alzheimer’s disease.
Explore the scienceAn investigational program. Clinical benefit remains to be established.
Our purpose
Alzheimer’s affects more than memory. It changes how people communicate, take part in daily activities, and live alongside the people they love.
The science
Synapses are the connections through which neurons communicate. Their loss is closely associated with cognitive impairment in Alzheimer’s disease.
Bryostatin-1 activates protein kinase C pathways, including PKCε. Preclinical research supports a hypothesis that these pathways could promote synaptic plasticity and repair. Whether this translates into meaningful benefit for patients requires clinical confirmation.
A research approach centered on the biological pathways involved in neuronal connections, cognition, and function.
Prior Alzheimer’s Phase 2 studies reported encouraging signals in selected patient subgroups. Overall efficacy has not been established.
A scalable chemical synthesis of Bryostatin-1 was published in 2017, providing a research pathway beyond reliance on marine supply.
Mechanistic findings are preclinical. Prior subgroup findings, including exploratory and post-hoc analyses, are a rationale for further research and do not establish clinical efficacy.
Clinical development
The proposed BRYGHT-AD study is designed to test Bryostatin-1 in the patient population associated with encouraging signals in earlier research, measuring cognition alongside everyday function.
Study details are planning proposals, subject to final protocol, statistical analysis plan, and applicable approvals. This page is not a recruitment announcement.
Prospective clinical partner
Ace Alzheimer Center Barcelona is a nonprofit foundation working across dementia care, research, training, and support for families.
Its multidisciplinary clinical infrastructure and established patient relationships underpin Neuracura’s proposed collaboration.
Foundation established
People served by its Diagnostic Unit in 2025
Active pharmacological trials in 2025
Source: Ace Alzheimer Center Barcelona, Activity Report 2025.
Further reading
Explore the program rationale and scientific background, alongside ACE’s own activity report.
Neuracura is developing an investigational Bryostatin-1 program focused on moderately severe Alzheimer’s disease. The objective is to study whether biological pathways associated with synaptic function could support cognition and everyday abilities.
The proposed BRYGHT-AD study would prospectively assess a defined patient population informed by earlier subgroup findings. Its design and timing remain subject to final protocol and applicable approvals. Clinical benefit has not been established.
Bryostatin-1 was originally isolated from a marine organism and investigated in National Cancer Institute oncology studies. Subsequent research examined its effects on protein kinase C pathways and synaptic biology.
Preclinical findings support further investigation of synaptic plasticity and repair. Prior Alzheimer’s trials reported signals in selected subgroups, including patients with moderately severe disease. Some analyses were exploratory or post hoc; the findings require prospective confirmation.
Prior human exposure does not establish that the drug is safe or effective for Alzheimer’s disease. The proposed study aims to evaluate cognition and daily function under a defined clinical protocol.
The foundation’s clinical care and research activity report for 2025. · PDF
Start a conversation
For scientific, partnership, and general inquiries.
info@neuracura.com